Navigation Links
GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

reating this complex form of breast cancer."

Despite receiving multiple prior lines of anti-cancer therapy, patients who received TYKERB plus trastuzumab in this study experienced:

-- A statistically significant increase in median progression-free survival

versus TYKERB alone (12 weeks vs. 8.1 weeks) (1)

-- A 27 percent reduction in the risk of disease progression [Hazard Ratio:

0.73; p=0.008] (1)

-- A response rate of 10.3 percent versus 6.9 percent. Response rate is a

clinical term that is calculated by complete and partial disappearance

of the tumor.

-- Double the overall clinical benefit rate versus TYKERB alone (24.7

percent vs. 12.4 percent; p=0.01) (1). Clinical benefit rate is

calculated by the response rate and the rate of durable stable disease

(greater than or equal to 6 months).

-- A trend in improved overall survival [Hazard Ratio: 0.75; p=0.106] (1)

The study also demonstrated the activity of TYKERB as a single agent in this patient population, with patients on this arm achieving a median progression free survival of 8.1 weeks and an overall clinical benefit rate of 12.4 percent (1).

The clinical synergy of TYKERB and trastuzumab confirms previous observational findings in preclinical studies and previously reported data from a Phase I study. These latest findings confirm the rationale for further research of this combination in earlier lines of therapy in the metastatic setting and in early stage disease. Additional analysis is underway to explore the benefit that TYKERB plus trastuzumab can offer to less heavily pre-treated patients (1).

Study Background

In this study, 296 patients with HER2 positive breast cancer who had documented progression on trastuzumab treatment in the metastatic setting were eligible to be randomized to receive TYKERB (1000 mg QD) plus trastuzumab (2 mg/kg weekly after 4 mg/kg lo

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
2. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
3. BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting
4. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
5. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
6. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
7. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
8. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
9. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
10. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
11. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
Post Your Comments:
(Date:10/9/2015)... India , October 9, 2015 ... analysis of major players. --> ... players. --> announces addition of ... status and 2020 forecasts for global markets as ... India along with analysis of major ...
(Date:10/9/2015)... 2015 Henry Schein , Inc. (NASDAQ: ... care products and services to office-based dental, animal health ... Henry Schein Disaster Relief Hotline is open for dentists, ... issues as a result of the disastrous flooding in ... for all Henry Schein customers is 800-999-9729. ...
(Date:10/9/2015)... , Oct. 9, 2015  Impax Laboratories, Inc. ... will release its third quarter 2015 financial results on ... the U.S. financial markets. The Company will host a ... at 8:30 a.m., Eastern Time on November 9, 2015.  ... . --> The financial results and live ...
Breaking Medicine Technology:
... IRVINE, Calif., Oct. 26 IDM Pharma, Inc.,(Nasdaq: ... the development of,innovative cancer therapies, today announced details ... pipeline compounds to be,presented at upcoming medical congresses. ... Mifamurtide (L-MTP-PE):, Connective Tissue Oncology Society (CTOS) ...
... Cell Therapeutics, Inc. (CTI) announces data presented at AACR-NCI-EORTC ... ... 26 Cell Therapeutics,Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems ... from several,of its drug candidates during the 19th annual AACR-NCI-EORTC Symposium. ...
Cached Medicine Technology:
(Date:10/9/2015)... ... October 09, 2015 , ... ... promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. This alternative ... invisible against the teeth, which allow patients to complete treatment in privacy. Additionally, ...
(Date:10/9/2015)... ... October 09, 2015 , ... The Asthma and Allergy Foundation ... for Disease Control and Prevention (CDC) to improve the knowledge and skills of underserved ... been awarded a project by the CDC and allows AAFA to continue vital efforts ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... welcoming individuals from all walks of life to save money on the high ... of $25 per month per medication, individuals and families can receive their medications ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... oldest and largest recreational dispensaries in Colorado, says the latest figures on the ... rapidly and maturing into a legitimate industry. , Last month, according to ...
(Date:10/9/2015)... ... , ... Smanos was featured on NewsWatch as part of its monthly Tech ... a technology expert and special reporter for NewsWatch, conducted the review and shared with ... this day and age it’s more important than ever to keep homes and dorms ...
Breaking Medicine News(10 mins):
... Idaho, March 18 RxElite, Inc. (OTC,Bulletin Board: RXEI), ... products, today announced it will discuss its,2007 year-end financial ... at 11:00 a.m. EDT., The Company will release ... Wednesday, March 19, 2008. Hosting the call will be,RxElite ...
... filing our,taxes and realize just how much money we handed ... wander onto the subject of how we can make,-- and ... you enjoy fitness and,an active lifestyle, you may want to ... typically making more money than personal trainers,employed by gyms, self-employed ...
... Leavitt,s Statement Is Contrary to Widely Held American ... President and CEO, Religious,Coalition for Reproductive Choice, ... Choice, the national coalition of mainstream religious and,religiously ... women,s reproductive healthcare and for women themselves in,the ...
... Texas, March 18 ULURU Inc. (Amex:,ULU) announced ... and Chief,Executive Officer, will provide a corporate presentation ... Conference in Boston, MA on March 20, 2008,at ... others may also listen to the presentation,hosted by ...
... Forces for Jude Andrew ... Adams Charitable Fund, CHICAGO, ... they have joined to offer Braun Pharmacy,customers free overnight shipping on ... individual cycles to the,Jude Andrew Adams Charitable Fund, a not for ...
... declines, Danish study found., , , TUESDAY, March 18 (HealthDay ... minute. If you just drop your average daily activity ... your car in the closest space, or by never walking ... diabetes, heart disease and premature death, according to new Danish ...
Cached Medicine News:
... Apparatus (patented) provides unparalleled reproducibility, speed and ... In combination with Elchrom Scientific AG ready-to-use ... require a regular submarine plus a vertical ... 2000 it is possible to get the ...
... ready-to-use gels are the key components of ... by submerged gel electrophoresis. We provide other ... compatibility and optimal performance, at a reasonable ... a unique staining tray, the system includes ...
Quick analysis of PCR products is now simple. The compact FastLane™ Chamber is designed for quick analysis of DNA fragments when used with our Reliant® FastLane™ Precast Gels....
... many advantages for nucleic acid separation, and ... molecular biologist. Agarose gels are easy to ... allow sample underlaying and prevent electrical field ... dehydration. Horizontal systems are more economical and ...
Medicine Products: